NCT04346862

Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 636 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	Acetyl-L-carnitine hydrochloride 500mg	The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
DRUG	Placebo	The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

Timeline

• Start date: 2016-01-26
• Primary completion: 2020-06-30
• Completion: 2020-06-30
• First posted: 2020-04-15
• Last updated: 2020-04-21

Locations

1 site across 1 country: South Korea